Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •Presence of cerebral metastases;
• •Confirmed positive for expression of expression of epidermal growth factor receptor (EGFR), activin receptor-like kinase (ALK), c-ros oncogene 1 (ROS1) mutation, or programmed death-ligand 1 (PD-L1)(tumor proportion score \[TPS≥ 50%\] in a genetic test;
• •Participants with malignant pleural effusion underwent intrapleural injection chemotherapy;
• •Current undergoing or preparing for treatment with target therapy;
• •Current undergoing or preparing for radiotherapy to the thorax;
• •Current undergoing or preparing treatment with tumor immunotherapy;
• •Currently undergoing lipid-decreasing treament;
• •Pregnant or breastfeeding woman;
• •Fertile patients who are unwilling or unable to take effective contraceptive measures during the research period until 6 months after the study end later;
• •A history of mental disorders；
• •Severe and uncontrolled organic lesion or infection, including but not limited to cardiopulmonary failure and renal failure，which lead to poor tolerance of chemotherapy;
• •Participated in other clinical trials of small molecule research drugs within 28 days prior to enrollment, or participated in other clinical trials of large molecule research drugs within 3 months before enrollment;
• •Known allergy or intolerance to study medications;
• •Considered to be otherwise unsuitable for the clinical study by researchers.